Serum time course of naltrexone and 6β-naltrexol levels during long term treatment in drug addicts

Drug and Alcohol Dependence

Volumn 52, Issue 3, 1998, Pages 211-220

  Ferrari, Anna ^a   Bertolotti, Marco ^a   Dell'Utri, Alessandra ^b   Avico, Ustik ^b   Sternieri, Emilio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

6 naltrexol; Bioavailability; Drug addicts; Drug interactions; Naltrexone; Pharmacokinetic

Indexed keywords

AMITRIPTYLINE; CLONAZEPAM; DESOGESTREL; DIAZEPAM; ESTRADIOL; LORAZEPAM; NALTREXOL; NALTREXONE; OPIATE ANTAGONIST; PHENDIMETRAZINE; THIORIDAZINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG METABOLISM; FEMALE; FIRST PASS EFFECT; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; FEMALE; HEROIN DEPENDENCE; HUMANS; LONG-TERM CARE; MALE; METABOLIC CLEARANCE RATE; NALTREXONE; NARCOTIC ANTAGONISTS;

EID: 0032213618     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(98)00098-2     Document Type: Article

References (31)

1. Atkinson L.R., Berke L.K., Drake C.R., Bibbs M.L., Williams F.L., Kaiser D.L. Effects of long-term therapy with naltrexone on body weight in obesity. Clin. Pharmacol. Ther. 38:1985;419-422.
2. Blaschke, T.F., Rubin, P.C., 1983. Hepatic first-pass metabolism in liver disease. In: Gibaldi, M., Prescott, L. (Eds.), Handbook of Clinical Pharmacokinetics. ADIS Health Science Press, Hong Kong, pp. 140-149.
3. Blumberg H., Ikeda C. Comparison of naltrexone and β-naltrexol for narcotic antagonist action in rats and mice. Fed. Proc. 35:1976;469.
4. Bardo M.T., Bhatnagar R.K., Gebhart G.F. Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat. Brain Res. 289:1983;223-234.
5. Bertolotti M., Ferrari A., Vitale G., Stefani M., Trenti T., Loria P., Carubbi F., Carulli N., Sternieri E. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J. Hepatol. 27:1997;505-511.
6. Bullingham R.E.S., McQuay H.J., Moore R.A. Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clin. Pharmacokinet. 8:1983;332-343.
7. Cone E.J., Gorodetzky C.W., Yeh S.Y. The urinary excretion profile of naltrexone and metabolites in man. Drug Metab. Dispos. 2:1974;506-512.
8. Dayton H.E., Inturrisi C.E. The urinary excretion profiles of naltrexone in man, monkey, rabbit and rat. Drug Metab. Dispos. 4:1976;474-478.
9. Gonzalez J.P., Brogden R.N. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 35:1988;192-213.
10. Jonas J.M., Gold M.S. Naltrexone reverses bulimic symptoms. Lancet. 1:1986;807.
11. Kogan M.J., Verebey K., Mulé S.I. Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. Res. Commun. Chem. Pathol. Pharmacol. 18:1977;29-34.
12. Licko, V., 1980. Overview of human pharmacokinetics of naltrexone. In: Willette, R.E., Barnett, G. (Eds.), Naltrexone Research Monograph 28. National Institute on Drug Abuse, pp. 161-171.
13. Maany I., O'Brien C.P., Woody G. Interaction between thioridazine and naltrexone. Am. J. Psichiatry. 144:1987;966.
14. Meyer M.C., Straughn A.B., Lo M.-W., Schary W.L., Whitney C.C. Bioequivalence, dose-proportionality, pharmacokinetics of naltrexone after oral administration. J. Clin. Psychiatry. 45:1984;15-19.
15. Meyer W.J., Woggon B., Baumann P., Meyer U.A. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur. J. Clin Pharmacol. 39:1990;613-614.
16. Misra, A.L., 1980. Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone. In: Willette, R.E., Barnett, G. (Eds.), Naltrexone Research Monograph 28. National Institute on Drug Abuse, pp. 132-145.
17. Navaratnam V., Jamaludin A., Raman N., Mohamed M., Mansor S.M. Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts. Drug Alcohol Depend. 34:1994;231-236.
18. Patwardhan R.V., Mitchell M.C., Johnson R.F., Schenker S. Differential effects of oral contraceptive steroids on the metabolism of benzodiazepines. Hepatology. 3:1983;248-253.
19. Pazzucconi F., Malavasi B., Galli G., Franceschini G., Calabresi L., Sirtori C.R. Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel. Clin. Pharmacol. Ther. 49:1991;278-284.
20. Peer G., Kivity S., Agami O., Fireman E., Silverberg D., Blum M., Laina A. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 348:1996;1552-1554.
21. 3H-Naltrexone to normal male volunteers. In: Willette, R.E., Barnett, G. (Eds.), Naltrexone Research Monograph 28. National Institute on Drug Abuse, pp. 93-101.
22. Pini L.A., Ferretti C., Trenti T., Ferrari A., Sternieri E. Effects of long-term treatment with naltrexone on hepatic enzyme activity. Drug Metab. Drug Interact. 9:1991;161-174.
23. Resnick R.B., Volavka J., Freedman A.M., Thomas M.R.N. Studies of EN-1639A (Naltrexone): a new narcotic antagonist. Am. J. Psychiatry. 131:1974;646-650.
24. Verebey K., Mulé S.J. Naltrexone pharmacology, pharmacokinetics, and metabolism: current status. Am. J. Drug Alcohol Abuse. 2:1975;357-363.
25. Verebey K., Kogan M.J., De pace A., Mulé S.J. Quantitative determination of naltrexone, 6β-naltrexol in human plasma using electron capture detection. J. Chromatogr. 118:1976;331-335.
26. Verebey K., Volavka J., Mulé S.J., Resnick R.B. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharmacol. Ther. 20:1976;315-328.
27. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry. 49:1992;876-880.
28. Wall, M.E., Brine, D.R., Perez-Reyes, M., 1980. The metabolism of naltrexone in man. In: Willette, R.E., Barnett, G. (Eds.), Naltrexone Research Monograph 28. National Institute on Drug Abuse, pp. 105-131.
29. Wall M.E., Brine D.R., Perez-Reyes M. Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug. Metab. Dispos. 9:1981;369-375.
30. Wolfhagen F.H.J., Sternieri E., Hop W.C.J., Vitale G., Bertolotti M., van Buuren H.R. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 113:1997;1264-1269.
31. Yobur B.C., Duttaroy A., Shah S., Davis T. Opioid antagonist-induced receptor upregulation: effects of concurrent agonist administration. Brain Res. Bull. 33:1994;237-240.